Global Ablation Devices Market - 2025 - 2033

Global Ablation Devices Market - 2025 - 2033

The global ablation devices market reached US$ 6.2 billion in 2024 and is expected to reach US$ 14.1 billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033.

Ablation devices are specialized medical instruments used in various therapeutic procedures to remove, destroy, or treat abnormal or diseased tissue through targeted energy. These devices are often used in minimally invasive procedures, offering precise and controlled methods of treatment with minimal damage to surrounding healthy tissues. Ablation is typically performed using various forms of energy such as heat, cold, electricity, or light. Ablation devices play a critical role in modern medicine, providing patients with safer, more efficient, and less invasive treatment options for a variety of medical conditions.

The ablation devices market is experiencing significant growth, driven by advancements in ablation devices, rising product launches and an increasing preference for minimally invasive procedures. For instance, in October 2024, Abbott achieved new major milestones to support the company's growing suite of pulsed-field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt PFA System and the launch of the FOCALFLEX trial to assess the company's TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation.

Market Dynamics: Drivers & Restraints

Rising technological advancements in ablation devices

The rising technological advancements in ablation devices are significantly driving the growth of the Ablation Devices market and are expected to drive the market over the forecast period. Technological advancements, particularly in imaging and guidance systems, have greatly enhanced the precision of ablation procedures. These innovations are broadening the scope of applications, reducing procedure times, improving patient outcomes, and expanding access to minimally invasive options.

The integration of advanced electroanatomical mapping systems has revolutionized its use in cardiology, especially for treating atrial fibrillation. The ability to map the heart’s electrical activity with precision has led to better success rates and lower recurrence of arrhythmias after treatment.

For instance, in October 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation (PFA) System.

Additionally, in October 2024, Medtronic plc announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density (HD) mapping and pulsed-field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter.

Robotic-assisted ablation systems are improving the accuracy and control of procedures. For instance, in December 2024, Stereotaxis Inc. and Chinese partner Shanghai Microport EP Medtech Co. Ltd. gained the National Medical Products Administration’s approval of its Magbot magnetic navigation ablation catheter for use with Stereotaxis’ robotic ablation system to treat drug-resistant cardiac arrhythmias in China.

Potential side effects and complications

Potential side effects and complications associated with ablation procedures are a significant challenge to the growth of the ablation devices market. These risks can deter patients and healthcare providers from adopting ablation technologies, limiting their widespread use. For instance, during radiofrequency or cryoablation for atrial fibrillation, there is a risk of causing esophageal injury or collateral damage to nearby nerves, such as the phrenic nerve, leading to complications like difficulty breathing.

Invasive procedures, such as catheter-based ablations, carry a risk of infection and bleeding at the insertion site. For instance, microwave ablation (MWA) or radiofrequency ablation (RFA) for liver tumors has been associated with post-procedural infections and bleeding, particularly in patients with pre-existing liver dysfunction or coagulopathies.

Additionally, laser ablation devices used for skin resurfacing or wrinkle reduction can sometimes lead to superficial burns or scarring, causing dissatisfaction among patients and tarnishing the reputation of such devices in cosmetic applications.

Ablation therapies, particularly for cardiac arrhythmias and certain tumors, may not always provide permanent results, leading to condition recurrence. For instance, atrial fibrillation patients treated with ablation may experience arrhythmia recurrence within a few years, requiring repeat procedures or alternative treatments.

Segment Analysis

The global ablation devices market is segmented based on technology, application, end-user and region.

Technology:

The radiofrequency ablation segment is expected to dominate the ablation devices market share

In cardiac ablation, radiofrequency ablation is most commonly used to treat atrial fibrillation (AF) and other arrhythmias by destroying or isolating the abnormal electrical pathways in the heart. The global prevalence of AF is increasing, leading to a growing demand for radiofrequency ablation devices. For instance, according to the National Institute of Health (NIH), the worldwide prevalence of atrial fibrillation is 37,574 million cases (0.51% of the worldwide population), increased by 33% during the last 20 years.

Radiofrequency ablation is also used in the treatment of chronic pain by targeting nerves that cause pain. It is especially used in conditions like osteoarthritis and back pain. This versatility in treating various pain conditions across multiple specialties has helped solidify radiofrequency ablation's market dominance. For instance, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain.

Advances in radiofrequency ablation technology, such as the development of more precise catheter designs, multi-electrode systems, and integrated mapping systems, have contributed to its increased efficiency and safety. For instance, in April 2024, a Minnesota-based medical technology company launched its OneRF Ablation System, which creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures. According to a release from NeuroOne Medical Technologies, this system is the company’s first device with a therapeutic indication. The thin-film, stereoelectroencephalopathy-guided radio frequency system is capable of both recording electrical activity and ablating nervous tissue while offering temperature control during surgical procedures.

Geographical Analysis

North America is expected to hold a significant position in the ablation devices market share

North America, particularly the United States, is a global leader in the development and adoption of cutting-edge medical technologies. Many of the world’s leading companies in the ablation devices market are based in North America, including Medtronic, Boston Scientific and Johnson & Johnson, which are pioneers in radiofrequency, cryoablation and microwave ablation technologies. The region continues to invest heavily in research and development, driving innovation in ablation devices.

For instance, in November 2024, Johnson & Johnson MedTech announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform for the treatment of drug-refractory paroxysmal Atrial Fibrillation (AFib). The VARIPULSE Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy.

The U.S. Food and Drug Administration (FDA) plays a critical role in the regulatory approval of medical devices, and its rigorous yet supportive framework for innovative technologies has helped speed up the availability of new ablation devices. Devices such as Medtronic's Arctic Front Cryoballoon and Biosense Webster's ThermoCool SmartTouch Catheter have received FDA approval, ensuring that North America remains at the forefront of adopting the latest and most advanced ablation technologies. This rising FDA approvals of advanced ablation devices is driving the market in the region.

For instance, in August 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced that several products in its market-leading cardiac ablation portfolio have received approval for a zero fluoroscopy workflow from the U.S. Food and Drug Administration (FDA). The products that can be used in this workflow include: THERMOCOOL SMARTTOUCH SF catheter, the most commonly used ablation catheter in the world for RF ablation, THERMOCOOL SMARTTOUCH Catheter, CARTO VIZIGO Bi-Directional Guiding Sheath, PENTARAY NAV ECO High-Density Mapping Catheter, DECANAV Mapping Catheters, and Webster CS Catheter.

Asia-Pacific is growing at the fastest pace in the ablation devices market

The prevalence of chronic conditions, such as cardiovascular diseases (CVDs), cancer and diabetes, is rapidly increasing in the Asia-Pacific region, fueling the demand for ablation therapies. Conditions like atrial fibrillation and liver cancer are becoming more common, and ablation is a preferred treatment for these diseases due to its minimally invasive nature.

For instance, as the incidence of cancer increases, particularly liver, lung and kidney cancers, the need for tumor ablation devices is also rising. The World Health Organization (WHO) forecasts that cancer cases in India will rise by 40% by 2030, further driving demand for ablation therapies.

The Asia Pacific region is seeing significant improvements in healthcare infrastructure, especially in countries like China, India, Japan, South Korea, and Australia. These countries are investing heavily in modern healthcare technologies, leading to increased adoption of advanced medical devices, including ablation technologies. Many hospitals and healthcare facilities are expanding their capacity to provide cutting-edge treatments, driving the demand for ablation devices.

For instance, in September 2024, Kauvery Hospital launched Fluoroless Ablation for Atrial Fibrillation, setting a new benchmark in the treatment of one of the most common heart rhythm disorders. Kauvery Hospital continues to push the boundaries of medical innovation to ensure that patients receive the most effective and minimally invasive treatments available.

Competitive Landscape

The major global players in the ablation devices market include Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Johnson & Johnson, Olympus Corporation, Stryker Corporation, Hologic, Inc., CONMED Corporation, Koninklijke Philips N.V., CooperSurgical, Inc. and among others.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global ablation devices market report delivers a detailed analysis with 62 key tables, more than 64 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.